Navigation Links
Sysmex America Begins Distribution of CellaVision® DM1200
Date:7/20/2010

MUNDELEIN, Ill., July 20 /PRNewswire/ -- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced the addition of the CellaVision® DM1200 cell image analysis analyzer to the Sysmex hematology product offering.  The DM1200 enables Sysmex America to meet the growing demand for automated cell image analysis, which improves both the quality of results and the productivity of laboratories performing mid-volume testing.    

The CellaVision® DM1200 opens up new ways of handling manual differentials traditionally performed on a microscope by automatically performing a preliminary differential count on peripheral blood. The analyzer pre-classifies the white blood cells, pre-characterizes parts of the red morphology and provides functionality for platelet estimation. By automating the manual differential, laboratories can experience enhanced turnaround times without sacrificing quality.  Its high degree of automation allows for an escalating workload without increasing labor.

"The CellaVision DM1200, which locates, identifies, and pre-classifies blood cells by means of automatic microscopy and advanced image processing, greatly enhances Sysmex America's hematology product offering.  We trust this addition to our hematology portfolio will serve our customers well as they continue to navigate through a challenging health care environment," said John Kershaw, President & CEO, Sysmex America, Inc.    

Sysmex America and CellaVision first initiated their working relationship in 2004.  Today, Sysmex Corporation and CellaVision have an extended and broadened working relationship via the completion of a recent global distribution agreement.  The agreement gives Sysmex a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide.  As of April 1, 2010, the non-exclusive agreement comprises all international markets but Canada.  

About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.  The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.  CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems.  Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.  For more information about Sysmex, please visit www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OhioHealth Installs Newest Version of Sysmexs Hematology Middleware, Sysmex WAM(TM) 4.0
2. Sysmex America Adds Industry Veteran to Company Leadership
3. Sysmex America Honored Second Consecutive Year as a Company That Cares
4. Sysmex America Announces Executive Leadership Changes
5. Sysmex America Announces Amerinet Urinalysis Contract
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. Aspirin Named 8th World Wonder by Majority of Americans
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology:
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... The ... and other communities across eastern Texas, is launching a cooperative charity drive with the ... families. , Serving more than 50,000 individuals and families in need, the Tarrant County ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to ... Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal implants ... the first office to be chosen by the dental implant manufacturer, Straumann, to bring ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism ... of this dance is to provide a night of fun for teens with and without ... help everyone feel welcomed and included at the event. The dance will take place on ...
(Date:2/12/2016)... Sacramento CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative ... progression of dental decay. With the recent approval by the FDA, there is a ... application similar to fluoride varnish, SDF is very simple and quick to apply. The ...
Breaking Medicine News(10 mins):